← Pharvaris N.V. (PHVS) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Pharvaris N.V. (PHVS)
Pharmaceutical Preparations · market cap $2.2B · as of 2026-07-16
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-11 (est.)
Earnings
Pipeline
3
programs
Upcoming events
3
next 90d+
Dossier
Ready
cached
Pharvaris N.V. (PHVS) is a clinical-stage pharmaceutical company with 118 employees and a ~$2.3B market cap, built almost entirely around deucrictibant, an oral treatment candidate for Hereditary Angioedema (HAE) in Phase 3. Two high-importance Phase 3 readouts are estimated in August 2026 and June 2027, making the next 12 months binary for the stock.
The catalyst path
- 2026-11-11 (est.)Earningsimp 5/10
- 2027-06-15 (est.)Phase 3 · Deucrictibantimp 9/10
- 2027-06-30Phase 3imp 8/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Deucrictibant low dose | Phase 2 | Hereditary Angioedema |
| Deucrictibant | Phase 3 | Hereditary Angioedema |
| Icatibant | Phase 3 | Intradialytic Hypotension |
Price & technical context
3-month
-5.8%
6-month
+9.5%
12-month
+30.0%
52-wk range
$20.96–$38.86
vs 50-day MA
-10.7%
vs 200-day MA
+2.7%
Realized vol
53.7%
Max drawdown
-52.7%
Daily closes through 2026-10-02. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for PHVS (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 3 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.